| pubmed-article:10188761 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10188761 | lifeskim:mentions | umls-concept:C0676831 | lld:lifeskim |
| pubmed-article:10188761 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:10188761 | pubmed:dateCreated | 1999-6-21 | lld:pubmed |
| pubmed-article:10188761 | pubmed:abstractText | The chimaeric monoclonal antibody basiliximab specifically binds the alpha subunit of the interleukin-2 (IL-2) receptor on activated T lymphocytes. Through competitive antagonism of IL-2, basiliximab supplements standard immunosuppressive therapy after renal transplantation. < or =24 Hours after a single intravenous dose of basiliximab 2.5 to 25 mg, approximately 90% of available IL-2 receptors on T lymphocytes were complexed with the drug. This level of basiliximab binding was maintained for 4 to 6 weeks when renal transplant patients received basiliximab 20 mg 2 hours before and then 4 days after transplantation surgery. In 2 large, well-designed trials, the percentage of patients with biopsy-confirmed acute rejection episodes after renal transplantation was significantly lower with basiliximab 20 mg (administered 2 hours before and then 4 days after transplantation surgery; 30 or 33%, respectively) than placebo (44 or 46%) at 6 months after surgery. Basiliximab was well tolerated during clinical trials. The incidence of infections (including active cytomegalovirus infection) and post-transplant lymphoproliferative disorders was similar with basiliximab and placebo. Cytokine release syndrome was not observed in patients who received basiliximab. | lld:pubmed |
| pubmed-article:10188761 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10188761 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10188761 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10188761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10188761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10188761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10188761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10188761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10188761 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10188761 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:10188761 | pubmed:issn | 0012-6667 | lld:pubmed |
| pubmed-article:10188761 | pubmed:author | pubmed-author:WisemanL RLR | lld:pubmed |
| pubmed-article:10188761 | pubmed:author | pubmed-author:OnrustS VSV | lld:pubmed |
| pubmed-article:10188761 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10188761 | pubmed:volume | 57 | lld:pubmed |
| pubmed-article:10188761 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10188761 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10188761 | pubmed:pagination | 207-13; discussion 214 | lld:pubmed |
| pubmed-article:10188761 | pubmed:dateRevised | 2005-11-17 | lld:pubmed |
| pubmed-article:10188761 | pubmed:meshHeading | pubmed-meshheading:10188761... | lld:pubmed |
| pubmed-article:10188761 | pubmed:meshHeading | pubmed-meshheading:10188761... | lld:pubmed |
| pubmed-article:10188761 | pubmed:meshHeading | pubmed-meshheading:10188761... | lld:pubmed |
| pubmed-article:10188761 | pubmed:meshHeading | pubmed-meshheading:10188761... | lld:pubmed |
| pubmed-article:10188761 | pubmed:meshHeading | pubmed-meshheading:10188761... | lld:pubmed |
| pubmed-article:10188761 | pubmed:meshHeading | pubmed-meshheading:10188761... | lld:pubmed |
| pubmed-article:10188761 | pubmed:meshHeading | pubmed-meshheading:10188761... | lld:pubmed |
| pubmed-article:10188761 | pubmed:meshHeading | pubmed-meshheading:10188761... | lld:pubmed |
| pubmed-article:10188761 | pubmed:meshHeading | pubmed-meshheading:10188761... | lld:pubmed |
| pubmed-article:10188761 | pubmed:year | 1999 | lld:pubmed |
| pubmed-article:10188761 | pubmed:articleTitle | Basiliximab. | lld:pubmed |
| pubmed-article:10188761 | pubmed:affiliation | Adis International Limited, Auckland, Mairangi Bay, New Zealand. demail@adis.co.nz | lld:pubmed |
| pubmed-article:10188761 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10188761 | pubmed:publicationType | Review | lld:pubmed |
